Finally, substantiating findings from our in vitro assays, our in vivo studies highlight the putative potential of CDH11-targeting to suppress tumorigenesis, and inhibit tumor growth in TNBC xenograft models, while concurrently improving survival time (Figure 6 and Figure S2). Here, CDH11 is linked to neoplasm.